Table 4 Neurocognitive outcomes from Handen et al.’s [61] open-label extension.

From: Effect of Alzheimer’s disease medications on neurocognitive outcomes in children and adolescents with autism spectrum disorder and low IQ: a scoping review

NC Domain

Assessment

Baseline

Endpoint

Week 0

Week 5

p

Week 10

p

Executive Function

TMTa

108.3 (42.7)

101.5 (48.6)

>0.05

98.0 (46.2)

>0.05

 

VF

8.15 (2.73)

  

8.23 (3.79)

>0.05

 

DFT

5.23 (2.59)

5.23 (2.28)

>0.05

5.69 (2.63)

>0.05

 

CWIa

87.4 (23.6)

87.2 (33.1)

>0.05

84.2 (26.9)

>0.05

 

STCCb

6.54 (2.11)

  

8.31 (1.70)

<0.01**

 

STFSc

23.15 (7.90)

  

30.92 (6.90)

<0.001***

Language

EOWPVT

110.7 (12.9)

111.6 (14.0)

>0.05

113.3 (14.4)

>0.05

Learning and Memory

SR

32.5 (6.1)

36.2 (6.1)

>0.05

35.8 (7.2)

>0.05

 

PAL

36.5 (5.7)

36.1 (8.3)

>0.05

37.0 (6.1)

>0.05

  1. TMT, trail making test; VF, verbal fluency; DFT, design fluency test; CWI, color-word interference; EOWPVT, expressive one word picture vocabulary test; SR, selective reminding; PAL, paired-associate learning test.
  2. aLower score at endpoints indicates improvement.
  3. bMeasured by Sorting Test (Delis-Kaplan Executive Function System) and indicates the number of correct sorts generated by the subject.
  4. cMeasured by Sorting Test (Delis-Kaplan Executive Function System) and indicates the number of correct verbal descriptions generated by the subject.
  5. **For comparison of treatment and control group, p-value < 0.01.
  6. ***For comparison of treatment and control group, p-value < 0.001.
Back to article page